We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Deciphera Pharmaceuticals Inc
1 own
7 watching
Current Price
$17.98
$0.11
(0.62%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
1,212.39M
52-Week High
22.76
52-Week Low
6.51
Average Volume
0.74M
Dividend Yield
--
P/E Ratio
--
Market Capitalization1,212.39M52-Week High22.7652-Week Low6.51Average Volume0.74MDividend Yield--P/E Ratio--What does the Deciphera Pharmaceuticals Inc do?
Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas. It is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for treatment of solid tumors and hematologic malignancies; and Rebastinib, which is in Phase 1b/II trial to treat solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.
Read More
How much money does Deciphera Pharmaceuticals Inc make?
News & Events about Deciphera Pharmaceuticals Inc.
Ticker Report
1hours ago
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH Get Rating) major shareholder Brightstar Associates Llc bought 1,666,666 shares of Deciphera Pharmaceuticals stock in a transaction that occurred on Tuesday, January 24th. The shares were acquired at an average cost of $18.00 per share, for a ...
Business Wire
7days ago
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the pricing of an underwritten public offering of 6,944,445 shares of its common...
Zolmax
21days ago
Deciphera Pharmaceuticals (NASDAQ:DCPH Get Rating) had its target price hoisted by research analysts at Barclays from $8.00 to $9.00 in a note issued to investors on Wednesday, The Fly reports. The firm currently has an underweight rating on the stock. Barclayss price target points to a potential ...
Business Wire
24days ago
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, at 9:45 AM PT. A live webcast of the event will be available on the Events and...
Ticker Report
1month ago
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH Get Rating) has earned an average rating of Moderate Buy from the eight ratings firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has ...
Frequently Asked Questions
Frequently Asked Questions
What is Deciphera Pharmaceuticals Inc share price today?
Can Indians buy Deciphera Pharmaceuticals Inc shares?
How can I buy Deciphera Pharmaceuticals Inc shares from India?
Can Fractional shares of Deciphera Pharmaceuticals Inc be purchased?
What are the documents required to start investing in Deciphera Pharmaceuticals Inc stocks?
What is today’s traded volume of Deciphera Pharmaceuticals Inc?
What is today’s market capitalisation of Deciphera Pharmaceuticals Inc?
What is the 52-Week High and Low Range of Deciphera Pharmaceuticals Inc?
What percentage is Deciphera Pharmaceuticals Inc down from its 52-Week High?
What percentage is Deciphera Pharmaceuticals Inc up from its 52-Week Low?
Current Price
$17.98
$0.11
(0.62%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.